Apr 28, 2025 | American Association for Cancer Research (AACR)Results of a first-in-human Phase 1 trial of anchored IL-12 drug conjugate (ANK-101)
Nov 9, 2024 | Society of Immunotherapy of Cancer (SITC):A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors
Nov 8, 2024 | Society of Immunotherapy of Cancer (SITC):Anchored immunotherapy with alum-tethered canine interleukin-12 (JEN-101) is safe and induces therapeutic responses: Results of a preclinical investigation in dogs with advanced melanoma
Jun 1, 2024 | American Society of Clinical Oncology (ASCO):A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors
Apr 5, 2024 | American Association for Cancer Research (AACR):Anchored IL-12 synergizes with an epigenetic modulator to promote immune remodeling and overcome anti-PD1-refractory murine tumors
Nov 3, 2023 | Society for Immunotherapy of Cancer (SITC):Improved immunologic and therapeutic activity of anchored interleukin (IL)-12 immunotherapy in combination with cytotoxic chemotherapy and immune checkpoint inhibitor in a head and neck cancer model
Oct 14, 2023 | Veterinary Cancer Society:Tolerability and Activity of Anchored Canine Interleukin-12 (cANK-101) in Pet Dogs with Advanced Malignant Melanoma
Oct 12, 2023 | European Organization for Research and Treatment of Cancer (EORTC):Preclinical pharmacokinetic (PK) and tumour growth inhibition (TGI) modelling for mANK-101, an anchored murine interleukin-12 (IL-12) complex for intratumoural administration for solid cancer
Apr 19, 2023 | American Association for Cancer Research (AACR)Preliminary Results of an Exploratory Phase I Clinical Trial of Anchored Canine Interleukin-12 (cANK-101) in Dogs with Advanced Oral Malignant Melanoma
Nov 10, 2022 | Society for Immunotherapy of Cancer (SITC) Presentation:Anchored immunotherapy with intratumorally administered aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response
Apr 10, 2022 | American Association for Cancer Research (AACR) Presentation:Intratumoral delivery of aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response
Oct 14, 2021 | Society for Immunotherapy of Cancer (SITC) Presentation:Intratumoral immunotherapy with aluminum hydroxide-tethered IL-12 induces potent local and systemic immunity with minimal toxicity
